News

LifeMD Expands Primary Care Platform’s Diagnostic Capabilities with New At-Home Screening Kits For Early Warning Signs Of Cancer

Patients can now access At-home kits for early warning signs of colon cancer and breast cancer through LifeMD’s primary care…

2 years ago

SOTIO Bolsters Leadership Team with Appointment of Martin Steegmaier as Chief Scientific Officer

PRAGUE, Czech Republic, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group,…

2 years ago

Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck…

2 years ago

SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million

Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com Marketplace TEL AVIV, Israel, Sept.…

2 years ago

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

- New preclinical data indicate IL-27 induces a gene expression signature that has been associated with resistance to chemotherapy, radiotherapy, and…

2 years ago

Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference

SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:…

2 years ago

BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™

Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive DisorderBURLINGTON, Mass. and JERUSALEM, Israel, Sept. 14, 2022 (GLOBE…

2 years ago

ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to…

2 years ago

OraSure Partners with Mars Petcare in One of the Largest Ever Microbiome Studies to Evaluate Pet Health

BETHLEHEM, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home…

2 years ago

Larimar Therapeutics Announces $70 Million Underwritten Offering

BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage…

2 years ago